Meadow Creek Investment Management LLC trimmed its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 34.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 8,512 shares of the medical research company’s stock after selling 4,508 shares during the quarter. Meadow Creek Investment Management LLC’s holdings in Charles River Laboratories Intl. were worth $956,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Mackay Shields LLC raised its stake in shares of Charles River Laboratories Intl. by 272.4% during the second quarter. Mackay Shields LLC now owns 46,182 shares of the medical research company’s stock valued at $5,184,000 after purchasing an additional 33,781 shares in the last quarter. Gamco Investors INC. ET AL raised its stake in shares of Charles River Laboratories Intl. by 40.0% during the first quarter. Gamco Investors INC. ET AL now owns 7,000 shares of the medical research company’s stock valued at $747,000 after purchasing an additional 2,000 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Charles River Laboratories Intl. during the first quarter valued at about $13,139,000. Douglass Winthrop Advisors LLC bought a new stake in shares of Charles River Laboratories Intl. during the second quarter valued at about $337,000. Finally, Principal Financial Group Inc. raised its stake in shares of Charles River Laboratories Intl. by 2.6% during the first quarter. Principal Financial Group Inc. now owns 207,753 shares of the medical research company’s stock valued at $22,176,000 after purchasing an additional 5,293 shares in the last quarter. Institutional investors own 97.76% of the company’s stock.

Shares of Charles River Laboratories Intl. stock opened at $124.28 on Thursday. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52. Charles River Laboratories Intl. Inc has a 52 week low of $96.70 and a 52 week high of $130.66. The stock has a market capitalization of $5.93 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 1.55 and a beta of 0.65.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The firm had revenue of $585.30 million for the quarter, compared to analysts’ expectations of $570.65 million. During the same period in the previous year, the business earned $1.29 earnings per share. Charles River Laboratories Intl.’s revenue for the quarter was up 24.8% compared to the same quarter last year. analysts predict that Charles River Laboratories Intl. Inc will post 5.91 earnings per share for the current year.

In other Charles River Laboratories Intl. news, CEO James C. Foster sold 5,005 shares of the business’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $110.80, for a total value of $554,554.00. Following the sale, the chief executive officer now directly owns 296,676 shares in the company, valued at $32,871,700.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Birgit Girshick sold 3,978 shares of the business’s stock in a transaction dated Tuesday, July 17th. The stock was sold at an average price of $119.90, for a total transaction of $476,962.20. Following the completion of the sale, the insider now owns 18,999 shares in the company, valued at $2,277,980.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,324 shares of company stock worth $4,504,045. 2.10% of the stock is owned by company insiders.

A number of equities research analysts recently weighed in on CRL shares. TheStreet upgraded shares of Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research note on Thursday, May 10th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 price objective on the stock in a research note on Friday, May 11th. Bank of America lifted their price objective on shares of Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Jefferies Financial Group lifted their price objective on shares of Charles River Laboratories Intl. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, SunTrust Banks lifted their price objective on shares of Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $125.40.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Trading Penny Stocks

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.